NCT05089019View on ClinicalTrials.gov

A Study Comparing Two Formulations of Selpercatinib (LY3527723) in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

224

Participants

Timeline

Start Date

October 29, 2021

Primary Completion Date

July 19, 2022

Study Completion Date

July 19, 2022

Conditions
Healthy
Interventions
DRUG

Selpercatinib

Administered orally

Trial Locations (4)

32117

LabCorp CRU, Inc., Daytona Beach

53704

LabCorp CRU, Inc., Madison

75247

Covance Dallas, Dallas

92801

Anaheim Clinical Trials, LLC, Anaheim

Sponsors
All Listed Sponsors
collaborator

Eli Lilly and Company

INDUSTRY

lead

Loxo Oncology, Inc.

INDUSTRY

NCT05089019 - A Study Comparing Two Formulations of Selpercatinib (LY3527723) in Healthy Participants | Biotech Hunter | Biotech Hunter